GlassScriptPhysician profile
Dawn Ngo
NPI 1194805978
$11,199.19
in general payments reported to CMS, 2019-2025
28 companies · $271 in 2025
The $271 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,555 · 2022: $2,414 · 2023: $2,527 · 2024: $3,433 · 2025: $271.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,034 · Education: $197.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,033.68 |
| Education | $197.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,241.22 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,317.52 | 2021-2025 | Entyvio, Gattex |
| Janssen Biotech, INC. | $1,228.49 | 2021-2025 | Stelara, Tremfya, Simponi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $772.66 | 2021-2025 | Xifaxan, Trulance, Relistor |
| Nestle Healthcare Nutrition INC. | $395.56 | 2021-2023 | |
| Pfizer INC. | $379.66 | 2021-2024 | |
| Gilead Sciences, INC. | $330.31 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $270.11 | 2022-2024 | Dupixent |
| Redhill Biopharma INC. | $263.95 | 2021-2024 | Talicia |
| Genzyme Corporation | $238.05 | 2022-2024 | |
| Aimmune Therapeutics, INC. | $226.22 | 2024-2025 | Zenpep |
| Ardelyx, INC. | $206.35 | 2022-2024 | Ibsrela |
| Celgene Corporation | $205.63 | 2021-2024 | Zeposia |
| Intercept Pharmaceuticals, INC. | $203.86 | 2021-2024 | Ocaliva |
| Phathom Pharmaceuticals, INC. | $166.57 | 2024 | Voquezna |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $151.49 | 2021-2022 | |
| Celltrion USA INC. | $124.00 | 2024-2025 | Zymfentra, Vegzelma |
| Organon LLC | $119.47 | 2021-2024 | Hadlima, Renflexis |
| Fresenius Kabi USA, LLC | $104.67 | 2023 | Idacio |
| Qol Medical, LLC | $71.84 | 2021-2022 | |
| Madrigal Pharmaceuticals | $48.67 | 2024-2025 | Resmetirom, Rezdiffra |
| Braintree Laboratories, INC. | $34.30 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $21.01 | 2024 | Iqirvo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.20 | 2024 | Cyltezo |
| Mylan Institutional INC. | $19.59 | 2023 | Ogivri |
| Biocon Biologics INC | $13.71 | 2025 | Yesintek |
| Daiichi Sankyo INC. | $12.07 | 2022 | |
| Evoke Pharma, INC. | $12.01 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dawn Ngo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.